Clinical Practice Guidelines in Cardio-Oncology.
Heart Fail Clin
; 18(3): 489-501, 2022 Jul.
Article
in En
| MEDLINE
| ID: mdl-35718421
ABSTRACT
Consensus statements on recommended definitions and practice in cardio-oncology have been developed. There is recognition of the potential for anthracyclines, trastuzumab, pertuzumab, immune checkpoint inhibitors, tyrosine kinase inhibitors, cyclophosphamide, and radiotherapy to cause left ventricular dysfunction and heart failure with heterogeneous natural histories. Cardiac function should be evaluated by echocardiography before the initiation of these therapies. For the prevention of cardiotoxicity, there is evidence to support the use of dexrazoxane under specific circumstances; existing research does not support the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or ß-blockers in unselected individuals but should be considered in specific instances.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ventricular Dysfunction, Left
/
Neoplasms
/
Antineoplastic Agents
Type of study:
Etiology_studies
/
Guideline
Limits:
Humans
Language:
En
Journal:
Heart Fail Clin
Year:
2022
Document type:
Article